Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer

Area of Science:

• Oncology
• Immunology
• Metabolic Research

Background:

• Colorectal cancer (CRC) arises from complex genomic and epigenomic alterations, impacting tumor-host interactions and leading to metabolic dysregulation.
• Glycolytic pathway dysregulation is a hallmark of CRC, influencing tumor initiation, progression, and systemic immunosuppression.
• Tumor cells manipulate host metabolism, affecting immune cell function, particularly T cells.

Purpose of the Study:

• To review recent findings on signaling molecules and genes in CRC's dysregulated glycolytic pathway.
• To discuss the role of metabolic alterations in CRC initiation, progression, and immunosuppression.
• To explore the interplay between CRC cells and T cells, focusing on metabolic pathways crucial for immune function.

Main Methods:

• Literature review of recent findings on colorectal cancer metabolism and immunology.
• Analysis of signaling pathways, downstream genes, and metabolic modulators in CRC.
• Examination of T cell metabolism and its inhibition by tumor-associated metabolic changes.

Main Results:

• Dysregulated glycolysis in CRC is linked to tumor growth and systemic immunosuppression.
• CRC cells induce glucose deprivation, inhibiting T cell glycolysis and effector functions.
• Metabolic pathways are critical for T cell function, differentiation, and activation.

Conclusions:

• Targeting metabolic pathways in CRC, particularly those affecting T cells, holds therapeutic potential.
• Selective metabolic inhibitors or immunomodulatory agents could enhance anti-tumor T cell responses.
• Personalized antigen identification and combination therapies are crucial for effectively targeting CRC metabolic pathways.